Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3582371 | 0.90 | HSD11B1 (0.52) | HSD11B1TRPA1NPSR1HTTPIK3CA | |
| SCHEMBL3878542 | 0.89 | TRPV1 (0.43) | HSD11B1TRPA1ADORA2AADORA1PIK3CA | |
| SCHEMBL3878966 | 0.85 | HSD11B1 (0.48) | HSD11B1TRPA1ADORA2AADORA1CNR2 | |
| SCHEMBL3884196 | 0.84 | HSD11B1 (0.53) | HSD11B1TRPA1NPSR1CNR2TRPV1 | |
| SCHEMBL3877647 | 0.83 | HSD11B1 (0.52) | HSD11B1TRPA1NPSR1PIK3CATRPV1 | |
| SCHEMBL3877143 | 0.80 | PIK3CA (0.53) | HSD11B1TRPA1NPSR1PIK3CACNR2 | |
| SCHEMBL3880843 | 0.80 | PIK3CA (0.53) | HSD11B1TRPA1NPSR1PIK3CACNR2 | |
| SCHEMBL3878605 | 0.80 | HSD11B1 (0.49) | HSD11B1TRPA1NPSR1PIK3CACNR2 | |
| SCHEMBL4029494 | 0.77 | TRPV1 (0.48) | ADORA2AADORA1LMNAKMT2AHTT | |
| SCHEMBL3883941 | 0.77 | ADORA2A (0.41) | ADORA2AADORA1LMNAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | HSD11B1 3915/4885TRPA1 714/4885ADORA2A 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.